Chemotherapy of Diffuse Astrocytoma (WHO grade II) in Adults.

Q2 Medicine

Progress in neurological surgery Pub Date : 2018-01-01 Epub Date: 2018-01-25 DOI:10.1159/000467375

Yoshitaka Narita

引用次数: 4

Abstract

The effectiveness of chemotherapy or chemoradiotherapy for diffuse astrocytoma (DA) has been largely unknown until recently. However, a randomized controlled study (RTOG 9802) showed that adding of procarbazine, CCNU, and vincristine (PCV) chemotherapy to fractionated radiotherapy (FRT) in patients with "high-risk" WHO grade II gliomas, including DA, has significant positive impact on both progression-free survival and overall survival. Effectiveness of temozolomide (TMZ) in cases of low-grade gliomas was also reported, and a randomized phase III trial comparing FRT alone or in combination with TMZ in cases of unresectable DA (JCOG 1303) is currently ongoing.

查看原文本刊更多论文

成人弥漫性星形细胞瘤(WHO分级II)的化疗。

化疗或放化疗治疗弥漫性星形细胞瘤(DA)的有效性直到最近才在很大程度上未知。然而，一项随机对照研究(RTOG 9802)显示，对于包括DA在内的“高风险”WHO II级胶质瘤患者，在分级放疗(FRT)的基础上加入丙卡嗪、CCNU和vincristine (PCV)化疗，对无进展生存期和总生存期都有显著的积极影响。替莫唑胺(TMZ)治疗低级别胶质瘤的有效性也有报道，目前正在进行一项比较FRT单独或联合TMZ治疗不可切除DA的随机III期试验(JCOG 1303)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Progress in neurological surgery Medicine-Surgery

自引率

0.00%

发文量

期刊介绍： Published since 1966, this series has become universally recognized as the most significant group of books serving neurological surgeons. Volumes feature contributions from distinguished international surgeons, who brilliantly review the literature from the perspective of their own personal experience. The result is a series of works providing critical distillations of developments of central importance to the theory and practice of neurological surgery.